Allogeneic stem cell transplant in renal failure: Engraftment and prolonged survival, but high incidence of neurologic toxicity

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 158-159

  Van Besien, Koen ^a   Schouten, Viviane ^a   Parsad, Sandeep ^a   Smith, Sonali ^a   Odenike, Olatoyosi ^a   Artz, Andrew S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGITATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AMNESIA; APHASIA; ASPERGILLOSIS; AUTOPSY; BRAIN HEMORRHAGE; CELL SURVIVAL; CLINICAL ARTICLE; CONFUSION; CRYOPRESERVATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LETHARGY; LETTER; MALE; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; PERIPHERAL T CELL LYMPHOMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SHORT TERM MEMORY; TREMOR;

AGED; FATAL OUTCOME; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RENAL DIALYSIS; RENAL INSUFFICIENCY; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84855424238     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.604756     Document Type: Letter

References (12)

1. Heher EC, Spitzer TR. Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol 2010;30:602-614.
2. Kersting S, Verdonck LF. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol.Blood Marrow Transplant 2008;14:1312-1316.
3. B adros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-829. (Pubitemid 32953738)
4. Horwitz ME, Spasojevic I, Morris A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with nd without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant 2007;13:1422-1426. (Pubitemid 350107733)
5. M assenkeil G, Roigas J, Nagy M, et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor eff ect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004;34:309-316. (Pubitemid 39172437)
6. Lavigne CM, Shrier DA, Ketkar M, et al. Tacrolimus leukoencephalopathy: a neuropathologic confi rmation. Neurology 2004;63: 1132-1133. (Pubitemid 39287937)
7. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031-1035.
8. Beitinjaneh A, McKinney AM, Cao Q, et al. Toxic leukoencephalopathy following fl udarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300-308.
9. Saiz A, Graus F. Neurologic complications of hematopoietic cell transplantation. Semin Neurol 2010;30:287-295.
10. V an Besien KW, Demuynck H, LeMaistre CF, et al. High dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant 1995;15:321-323.
11. S inghal S, Powles R, Treleaven J, et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996;18:1049-1055. (Pubitemid 27026259)
12. B adros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20: 1295-1303. (Pubitemid 34177436)